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ABSTRACT
Measles virus (MV) is the only human virus within the morbillivirus genus of the Paramyxoviridae. The
veterinary members are canine distemper virus (CDV), peste des petits ruminants virus (PPRV), Rinderpest
Virus (RPV) as well as the marine morbilliviruses phocine distemper virus (PDV), dolphin morbillivirus
(DMV) and porpoise morbillivirus (PMV). Morbilliviruses have a severe impact on humans and animal
species. They confer diseases which have contributed to morbidity and mortality of the population on a
global scale. There is substantial evidence from both natural and experimental infections that
morbilliviruses can readily cross species barriers. Of most concern with regard to zoonosis is the more
recently reported fatal infection of primates in Japan and China with strains of CDV which have adapted to
this host. The close genetic relationship, shared cell entry receptors and similar pathogenesis between the
morbilliviruses highlights the potential consequences of complete withdrawal of MV vaccination after
eradication. Therefore, it would be prudent to continue the current MV vaccination. Ultimately
development of novel, safe vaccines which have higher efficacy against the veterinary morbilliviruses is a








Measles virus (MV) is the only human virus within the morbil-
livirus genus of the Paramyxoviridae. The veterinary members
are canine distemper virus (CDV), peste des petits ruminants
virus (PPRV), Rinderpest Virus (RPV) as well as the marine
morbilliviruses phocine distemper virus (PDV), dolphin mor-
billivirus (DMV) and porpoise morbillivirus (PMV). The
World Health Organization (WHO) has set goals towards the
eventual elimination of MV in 2020,1 however, there is poten-
tial for new morbillivirus strains from alternative zoonotic res-
ervoirs to move into the ecological niche if MV eradication is
achieved and vaccination withdrawn. As found by phlyloge-
netic studies, MV shares closest similarity with the now eradi-
cated RPV.2,3 This, along with examples of successful cross-
species transmission in other RNA viruses, such as Influenza4
and the SARS and MERS Coronaviruses,5 highlights the poten-
tial risk and possible consequences of cross-species infection
and the case for continued MV vaccination or alternatively use
of more efficacious specifically designed vaccines.
Measles and morbillivirus diseases
Morbilliviruses have a severe impact on humans and animal
species. They confer diseases which have contributed to
morbidity and mortality of the population on a global scale.
All morbillivirus infections result in lymphopenia and cause
the host to be immunosuppressed which allows the invasion
of secondary bacterial infections adding to the morbidity
and mortality. The characteristic maculopapular rash associ-
ated with MV is thought to be caused by the T-cell
response to the infection as often individuals with an
immunodeficiency do not display this symptom.6 The virus
is transmitted by aerosol droplets and can cause respiratory
distress as well as damage to the bronchioles and cilia lining
the respiratory tract.7 It is known to replicate in lymphoid
tissues and organs but also affects the skin, lung, conjuncti-
vae and the gastrointestinal (GI) tract. This damage to the
GI tract is also seen in other members of the morbillivirus
genus, particularly the now eradicated RPV.2,8 PDV and
DMV result in lesions in the lung, lymphoid and central
nervous tissues which is similar to symptoms observed with
infection by CDV.9,10 Infection of the central nervous sys-
tem (CNS) also occurs with morbillivirus species which, in
the case of MV, can result in acute post infection encephali-
tis (1 in 1,000 cases), subacute sclerosing panencephalitis
(SSPE) (up to 1 in 10,000 cases) and measles inclusion
body encephalitis (MIBE) which occurs in immunosup-
pressed individuals.11,12 In contrast to MV, it is usual for
the marine morbilliviruses and CDV to infect the CNS in
their natural hosts. A rare form of encephalitis which bears
resemblance to SSPE, also occurs in mature dogs and is
known as ‘old dog encephalitis’.13 It presents symptoms
including extensive perivascular cuffs and intranuclear viral
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inclusions which are also associated with SSPE. CDV is
most likely the etiological agent in this manifestation of dis-
ease as it was detected through molecular assays and immu-
nohistochemical techniques.13
There is substantial evidence from both natural and experi-
mental infections14,15 that morbilliviruses can readily cross spe-
cies barriers. This is not surprising considering their common
origin from a postulated common ancestral virus. MV is
thought to have evolved from the now eradicated cattle morbil-
livirus, RPV, by entering the human population during cattle
domestication.16 Although RPV is now eradicated, this high-
lights the potential consequences of complete withdrawal of
MV vaccination after eradication. Of most concern with regard
to zoonosis is the more recently reported fatal infection of pri-
mates in Japan and China with strains of CDV which have
adapted to this host. In 1989 a case of encephalitis in a Japanese
monkey (Macaca fuscata) occurred17 and more recently on a
Guangxi breeding farm approximately 10,000 animals were
infected with CDV with between 5%–30% mortality. The epi-
demic was controlled by vaccination.18 An outbreak of CDV in
20 hand-feeding Rhesus monkeys was later reported in
Beijing.19
Morbillivirus proteins
One of the major factors in virus adaptation to another species
is mutations in the virus protein(s) which allow use of the cell
entry receptors of the new host. Morbilliviruses encode six
structural and two non-structural proteins. Within the internal
helical nucleocapsid, comprised of the nucleoprotein (N), the
phosphoprotein (P) and the large protein (L), is the RNA
genome which forms a ribonucleoprotein complex together
with the RNA dependent RNA polymerase (RdRp).20 The L
protein activates the enzyme RdRp through its interactions
with the P and N proteins. This enzyme is responsible for the
transcription and replication of the virion genome and also car-
ries out modifications of the mRNAs post-transcriptionally.
This enzyme, however, has little proof-reading ability and
accounts for the high mutation rate associated with RNA
viruses. The non-structural proteins, C and V, are encoded
from the P protein gene and have been shown to have roles as
interferon antagonists modulating the immune response.21–23
The virus is enveloped by a lipid bilayer which is formed from
the host cell when budding from the plasma membrane occurs.
This envelope contains three structural proteins the matrix pro-
tein (M) which presents a boundary between the nucleocapsid
and the envelope and plays a role in the transcription and bud-
ding of the virus24,25 by interacting with the haemagglutinin
(H) protein and the fusion (F) protein.
The H protein is the most important protein in mediating
the viral attachment to a specific receptor. The attachment of
virus brings about a conformational change in both the H and
F proteins. This change in the F protein allows the fusion of the
virus with the host cell membrane and the subsequent entry of
the nucleocapsid.26,27 Knowledge of these proteins and their
interactions with the host along with sequence similarities
among different morbillivirus species provides invaluable infor-
mation on the mechanisms used by the virus and the risk of
cross- species infection.
Morbillivirus cell entry
Several receptors have been identified and characterized in their
role in viral entry of MV and the veterinary morbilliviruses.
Signalling Lymphocyte Activation Molecule (SLAM), a mem-
brane glycoprotein, has been reported as an MV receptor on
immune cells. This molecule has also been shown to act as a
receptor for CDV, RPV, PPRV, PDV and DMV.28–32 It has also
been found that these viruses can use SLAM receptors of non-
host species albeit with lower efficiencies.31 The SLAM receptor
is selectively expressed on cells of the immune system and can
account for the lymphotropism, lymphopenia and immunosup-
pression of infected individuals.33,34
More recently an adherens junction protein, poliovirus-
receptor-like-4 (PVRL-4) also known as Nectin-4 was identi-
fied as the epithelial receptor for MV.35,36 The veterinary
morbilliviruses have also been shown to use their species spe-
cific nectin-4 molecules.32,37 This receptor is expressed on the
basal but not apical surface of epithelial cells and would there-
fore not allow entry to the respiratory tract. Instead virus entry
is considered to occur through SLAM expression on dendritic
cells. Nectin-4 would mediate the exit of virus back into the air-
ways and spread of the virus to other individuals via aerosol
transmission.38,39
Nectin-4 has also been shown to be expressed extensively in
canine brain tissue where it could also have a role as a cell entry
receptor. Nectin-4 was detected in ependymal cells, epithelia of
choroid plexus, meningeal cells, neurons, granular cells, and
Purkinje’s cells. CDV antigens were detected in these nectin-4-
positive cells, further indicating a role of nectin-4 in CDV neu-
rovirulence.40,41 Studies suggest that the expression pattern of
nectin-4 in the CNS differs greatly between dogs and humans.
The molecule is difficult to detect in human brain samples35,36
which could be a factor in why MV CNS infection in humans is
a much rarer event then that of CDV or the marine morbillivi-
ruses in their respective hosts.
The major route for morbillivirus entry to the CNS is con-
sidered to be across the blood-brain-barrier (BBB) via the cere-
bral endothelium.42–44 We have recently shown that nectin-4
cannot be detected by antibody staining and mRNA is only
found at very low levels in human brain endothelial cell cul-
tures. However, when these cultures are inoculated with wild
type (wt) MV the protein is highly expressed.45 Therefore, MV
may possibly up-regulate the receptor on endothelial cells at
the BBB providing a CNS entry mechanism. However, this
would not allow spread into other cells in the brain paren-
chyma such as neurons and oligodendrocytes. Similarly, astro-
cytes in canine brain do not express nectin-4, although they are
frequently infected with CDV.46 Since astrocytes are negative
for SLAM expression, they must express an unidentified CDV
receptor, which would also contribute to CDV neurovirulence.
This raises the possibility of one or more further receptors for
infection of the human and canine CNS by morbilliviruses.
Adaption to receptors in vitro
Other receptors have been found to facilitate morbillivirus cell
entry in vitro. CD46, a membrane co-factor protein is widely
expressed on human and other primate cells.47,48 While CD46
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has been confirmed as a MV receptor it was found to only
mediate the entry of adapted vaccine strains in vitro but not wt
MV. This was shown to be due to amino acid substitutions in
the virus H protein. It has been proposed that the lack of CD46
using viruses in vivo may be due to the down regulation of the
protein by MV in infected cells following cell entry.49,50
Unlike wt MV and wt CDV, we found that wt strains
of PDV were able to infect African Green Monkey Vero cells
with no prior adaptation. In common with RPV and CDV, we
have demonstrated that wt PDV does not utilise CD46 as a
receptor.31 There is evidence to suggest that CDV H protein
interacts with an unknown cellular receptor(s) regulated by
CD9, a member of the tetraspan transmembrane- protein fam-
ily.51 CD46 has been shown to form a complex with CD9,
beta1 integrins and the membrane bound form of heparin-
binding EGF-like growth factor (pro-HB-EGF).52,53 We found
that infection of wt PDV in Vero cells was inhibited by anti-
body to HB-EGF and that virus replicated in CHO-pro-HB-
EGF cells, indicating use of this molecule as a receptor.32
Adaptive mutation to cell entry receptors
We now know that two cell entry receptors are shared across
the morbilliviruses, SLAM on immune cells and Nectin-4 on
the basal surface of epithelial cells. Furthermore, little or no
virus mutation is required for use of these molecules in differ-
ent species. Langedijk et al.54 identified 11 residues on one side
of CDV H protein which contains distinct and overlapping sites
that control functional interaction with multiple receptors.
Some of these amino acids map onto SLAM and the Nectin-4
binding site. Removal of these sites abrogates binding for MV
but not CDV. Sequence analysis of the H gene of three CDV
strains adapted to monkeys revealed a glycine (G) and a tyro-
sine (Y) at amino acid positions 530 and 549 of the partial
SLAM-receptor binding region of the CDV H protein. G530
and Y549 are typically found in viral strains obtained from
domestic dogs in China rather than wildlife viruses. The three
monkey CDV strains possessed E276V, Q392R, D435Y and
I542F substitutions, which are unique changes when compared
to the other Asia type I lineage strains. In particularly, the
I542F substitution falls with the SLAM-binding regions of the
H protein. The CDV monkey-BJ01-DV strain was shown to
efficiently use monkey- and dog-origin SLAM to infect and rep-
licate in host cells, but further adaptation is likely to be required
for efficient replication in host cells expressing the human
SLAM receptor.55
Vaccination
The MV vaccine is generally given as part of the measles,
mumps and rubella (MMR) vaccine, all live attenuated viruses.
One dose of MMR vaccine is on average 93% effective for mea-
sles while two doses are 97% effective. Both serologic and epi-
demiologic evidence indicate that vaccine-induced measles
immunity appears to be long-term and probably lifelong in
most individuals.56 Many of the attenuated strains in use are
derived from the Edmonston strain isolated in 1954, including
the Schwartz, the Edmonston-Zagreb, and the Moraten strains.
Other strains which are not derived from Edmonston strain
include the CAM-70, TD 97, Leningrad-16, and Shanghai 191
(Ji-191) strains. The attenuated production virus is replicated
in primary chick embryo or other cell cultures, the virus har-
vested, clarified, and (alone, or with other antigens) lyophilized
(WHO website). The MV vaccine is extremely safe due to the
very low risk of reversion but is still unlikely to be acceptable in
a measles free world raising the need for alternative approaches.
A formalin fixed MV vaccine was used for a period in the 1960s
but provided short lived and non-complete immunity with an
altered immune response and death of some children following
later infection.57 Vaccines against rinderpest and measles has
led to the eradication of the former and the greater control of
the latter. Vaccines against PPR and canine distemper have
also been generated; however, the diseases still pose a threat to
susceptible species.58
Canine distemper virus immune-stimulating complexes
(iscoms), but not measles virus iscoms were found to protect
dogs against CDV infection.59 In MV vaccinated macaques
experimentally infected with CDV the disease was found to be
self-limiting. However, virus shedding still occurred from the
upper respiratory tract, albeit at lower levels than in non-vacci-
nated animals.60 Therefore, to protect the human population
against potential zoonotic events by CDV and/or other veteri-
nary morbilliviruses we will need vaccines which unlike the
current MV vaccine would prevent virus shedding and hence
human to human virus transmission. This is encouraging
research into alternative types of vaccines which would be a pri-
ority to have in place when MV is eventually eradicated.
Conclusions
The commonality of morbillivirus receptors and the ability of
these viruses to adapt to use other host species cells in culture
provides a basis for assessing the risk of animal to human trans-
mission of the veterinary morbilliviruses when MV is eventu-
ally eradicated. Currently, there is minimal risk of human
infection due to the monoserotypic characteristic of morbillivi-
ruses which means that individuals who have received the rou-
tine vaccination have a level of protection against other
members of this genus. However, the recent adaptation of
CDV to non-human primates and associated mutations in the
virus H protein increases the possibility of morbillivirus zoono-
sis, particularly further adaptation of CDV monkey strains to
humans. In view of this prospective it would be prudent to con-
tinue MV vaccination in the immediate future following eradi-
cation. Furthermore, there is a priority to develop of novel, safe
vaccines for humans which would more fully protect against
the veterinary mobilliviruses by providing sterilizing immunity.
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